ReviewInflammopharmacology2026
MicroRNA-mediated regulation of inflammatory gene expression in asthma.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a long-term inflammatory condition of the airways that includes complex immune dysregulation, epithelial barrier issues, and structural remodelling. The critical function of the miRNAs as modulators of inflammatory gene expression in asthma is highlighted by recent studies. It regulates immune cell development, cytokine production, and important signalling pathways like MAPK, JAK/STAT, and NF-κB. The let-7 family, miR-21, miR-155, and miR-126aresignificantin Th2-driven eosinophilic asthma and inflammation caused by neutrophils. Smooth muscle cell growth and epithelial cell transformation are two ways that disrupt the miRNA networks that impact the airways. Early laboratory studies have demonstrated the potential of the miRNA mimics and antagomirs as treatment methods. However, targeting issues, undesirable interactions, and long-term safety concerns make their application difficult in medical diagnosis. This review describes phenotype-specific miRNA patterns, evaluates their biomarker potential in disease severity and therapy response, updates and critically summarises miRNA biogenesis, and contrasts new miRNA approaches with existing biologic therapies.
Indexed as
Identifiers
42247122What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.